AACR data shows promise for patients with solid tumour types
Data from the Friends of Cancer Research’s (Friends’) ctMoniTR Project, recently published in Clinical Cancer Research (CCR), demonstrate a strong association between changes in levels of circulating tumour DNA (ctDNA) and treatment outcomes. This offers the potential for integration of ctDNA analysis in therapeutic development programmes, and clinical cancer care.
ctDNA holds promise as an early endpoint to predict overall survival (OS). The creation and structured interrogation of aggregated datasets inform the hypothesis that ctDNA is reasonably likely to predict treatment benefit. Friends convened a diverse working group to establish and implement an analysis plan assessing patient-level associations between changes in ctDNA levels with OS and progression-free survival (PFS).
The ctDNA to Monitor Treatment Response (ctMoniTR) Project was designed to determine whether changes in levels of ctDNA predict treatment outcomes for patients.
Experimental design and results
The aggregate dataset included eight clinical trials representing 940 patients with biomarker-positive advanced non–small cell lung cancer treated with tyrosine kinase inhibitors. Detection of baseline and on-treatment ctDNA was assessed for associations with OS and PFS. Additionally, combinations of ctDNA detection and RECIST measurements up to 10 weeks on treatment were considered.
Results from the first phase of the project demonstrated a strong link between changes in ctDNA and overall survival in patients with aNSCLC treated with immune checkpoint inhibitors (published in the Journal of Clinical Oncology). The new data, from the second phase of ctMoniTR, expands the analysis to additional solid tumour types and treatment categories, including patients treated with tyrosine kinase inhibitors.
Patients with detected ctDNA at baseline that became non-detected on treatment (clearance) experienced improved OS compared with patients with persistently detected ctDNA (adjusted HR = 2.12, P < 0.001). This pattern was also seen in the subset of patients with stable disease as measured by RECIST within 10 weeks of treatment initiation (adjusted HR = 4.15, P < 0.001). Results were similar for PFS.
In patients with oncogene-driven advanced non–small cell lung cancer treated with tyrosine kinase inhibitors, ctDNA clearance within 10 weeks of treatment initiation was associated with improved OS and PFS. These patient-level results support the growing evidence that demonstrates a change in ctDNA levels during treatment is associated with clinical benefit. Future prospective trials should include predefined thresholds of molecular response to advance the utility of ctDNA as an early endpoint.
Collaborators
Led by Friends, collaborators included Biodesix, alongside organisations from industry, government, academia, and advocacy groups. Biodesix contributed data generated using Bio-Rad Droplet Digital PCR (ddPCR) technology to detect ctDNA from patient samples.
“Biodesix is proud to be a partner on this important project, which has the potential to support a transformation of therapeutic development and clinical cancer care,” said Gary Pestano, Chief Development Officer at Biodesix.
Steve Kulisch, Vice President Product Management, Digital Biology Group, Bio-Rad Laboratories, said: “These collaborations and research programmes are vital as we work towards establishing novel methods for molecular residual disease monitoring in oncology, supporting the advancement of scientific research and ultimately healthcare.”
Megan Thomas, Multimedia Editor, DDW
